Despite advancements in immune checkpoint inhibitors, metastatic uveal melanoma (mUM) continues to exhibit limited responses due to its low tumor mutational burden (TMB) and reduced PD-L1 expression, which impairs neoantigen recognition by tumor-specific T cells [110–112]. This evidence concerns the gene CD274 and neoplasm.